Company news
Icecure Medical Ltd. (NASDAQ:ICCM) news
Icecure Medical Ltd. news releases on 6ix. Latest, Mar 19, 2024: IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study…
Press releases — page 3
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
March 18, 2024
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
March 11, 2024
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
January 29, 2024
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
January 11, 2024
IceCure's ProSense® Deepens Regulatory Approval in India
November 28, 2023
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
November 27, 2023
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
November 14, 2023
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
November 14, 2023
Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%
October 4, 2023
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate
October 1, 2023
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer
September 19, 2023
IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil
September 4, 2023
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America
August 27, 2023
IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
August 13, 2023
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023
August 6, 2023
Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System
July 23, 2023
IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales
July 16, 2023
IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country
May 30, 2023
IceCure Medical Reports First Quarter 2023 Financial & Operational Results
May 21, 2023
IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange
April 18, 2023
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes
March 27, 2023
IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights
February 8, 2023
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems
January 17, 2023
IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
December 22, 2022
IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
December 20, 2022
IceCure Medical Ltd. Announces Proposed Public Offering
December 19, 2022
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results
December 18, 2022
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors
December 5, 2022
IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights
December 4, 2022
IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
November 27, 2022
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures
November 7, 2022
IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month
October 25, 2022
IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery
October 18, 2022
IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil
October 10, 2022
IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®
August 28, 2022
IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights
August 14, 2022
IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
July 24, 2022
IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China
June 12, 2022
IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil
June 8, 2022
IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights
May 17, 2022
IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022
May 10, 2022
IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology
April 26, 2022
IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results
January 30, 2022
IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option
December 12, 2021
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering
December 8, 2021
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources
November 28, 2021
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments
November 22, 2021
IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™
October 31, 2021
IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSense™ Cryoablation System
October 19, 2021
IceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3® System to Treat Cancerous Tumors with Cryoablation
October 11, 2021